Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population‐based study

Data on treatment and survival of patients with advanced unresectable esophageal squamous cell carcinoma (ESCC) from Western populations are limited. Here we describe treatment and survival in patients with advanced unresectable ESCC: patients with cT4b disease without metastases (cT4b), metastases...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2022-03, Vol.113 (3), p.1038-1046
Main Authors: Pape, Marieke, Vissers, Pauline A.J., de Vos‐Geelen, Judith, Hulshof, Maarten C.C.M., Gisbertz, Suzanne S., Jeene, Paul M., van Laarhoven, Hanneke W.M., Verhoeven, Rob H.A.
Format: Article
Language:English
Subjects:
Aged
Cancer therapies
Chemoradiotherapy
Chemotherapy
Clavicle
Diagnosis
distant metastases
Esophageal cancer
Esophageal Neoplasms - mortality
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
esophageal squamous cell carcinoma
Esophageal Squamous Cell Carcinoma - mortality
Esophageal Squamous Cell Carcinoma - pathology
Esophageal Squamous Cell Carcinoma - therapy
Esophagus
Female
Humans
Lymph nodes
Lymphatic system
Male
Medical records
Metastases
Metastasis
Middle Aged
Netherlands - epidemiology
Original
palliative treatment
Patients
Pneumonectomy
Population
Population studies
Population-based studies
Radiation therapy
Registries
Retrospective Studies
Squamous cell carcinoma
supraclavicular lymph node metastases
Survival Rate
Tumors
unresectable advanced disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data on treatment and survival of patients with advanced unresectable esophageal squamous cell carcinoma (ESCC) from Western populations are limited. Here we describe treatment and survival in patients with advanced unresectable ESCC: patients with cT4b disease without metastases (cT4b), metastases limited to the supraclavicular lymph nodes (SCLNM) or distant metastatic ESCC at the population level. All patients with unresectable (cT4b) or synchronous metastatic ESCC at primary diagnosis (2015‐2018) or patients with metachronous metastases after primary non‐metastatic diagnosis in 2015‐2016 were selected from the Netherlands Cancer Registry. Fifteen percent of patients had cT4b disease (n = 146), 12% SCLNM (n = 118) and 72% distant metastases (n = 681). Median overall survival (OS) time was 6.3, 11.2, and 4.4 months in patients with cT4b, SCLNM, and distant metastases, respectively (P 
ISSN:1347-9032
1349-7006
1349-7006
DOI:10.1111/cas.15262